asian population with type 2 diabetes mellitus: a 4-year prospectiveanalysis. Arch Intern Med 2010; 170: 155–161. 12 Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.Circulation 2009; 120: 2177–2187. 13 Rein P, Saely CH, Beer S, Vonbank A, Drexel H. Roles of the met- abolic syndrome, HDL cholesterol, and coronary atherosclerosis insubclinical inﬂammation. Diabetes Care 2010; 33: 1853–1855. 14 Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3):an open-label randomised trial. Lancet 2010; 375 : 2234–2243.DIABETIC Medicine DURATION-2: switching from sitagliptin or pioglitazone to exenatide once-weekly •C. Wysham et al. ª2011 Amylin Pharmaceuticals, Inc. 714 Diabetic Medicine ª2011 Diabetes UK